Investor Relations
Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Investor Relations
Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Financial and Operational Metrics
(As of September 30, 2024)
-
$164M
TTM Revenue
-
$20M
TTM Adjusted EBITDA
-
$63M
Cash balance
with no debt
-
#1
OA Pain
U.S. Market Share
~25M
Injections
Worldwide
Current Investor Presentation
Latest Quarterly Results
Q3 2024 Earnings
Investor Contacts
Primary IR Contact
-
Matt Hall
Director, Corporate Development and Investor Relations
Anika Therapeutics, Inc.
Phone: (781) 457-9554
Email: investorrelations@anika.com
-
Transfer Agent
Equiniti Trust Company LLC
6201 15th Avenue
Brooklyn NY 11219
Phone: (800) 937-5449
Want Alerts? Sign up for alerts and never miss an Investor update!